First in human single-ascending dose study: Safety, biomarker, pharmacokinetics and exposure-response relationships of ALXN1210, a humanized monoclonal antibody to C5, with marked half-life extension and potential for significantly longer dosing intervalsleonardo sahelijo, MD,1

Authors
Category Primary study
JournalBlood
Year 2015
This article has no abstract
Epistemonikos ID: 21eca11972b78ea7534b98067eeb6db8f4a1f375
First added on: Feb 07, 2025